Sanjeev Deva

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Jayesh Desai, Sanjeev Deva, Jong Seok Lee et al. · Journal for ImmunoTherapy of Cancer · 2020 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial

Reuben Broom, Victoria Hinder, Katrina Sharples et al. · Clinical Genitourinary Cancer · 2014 · 40 citations

Medicine, Nephrology, Oncology +17

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Ezra E.W. Cohen, Lisle M. Nabell, Deborah J. Wong et al. · Journal of Clinical Oncology · 2019 · 31 citations

Life Sciences, Immunology, Oncology +17

Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Adrian G. Sacher, Wilson H. Miller, Manish R. Patel et al. · Journal of Clinical Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors

Sanjeev Deva, J.-S. Lee, C.-C. Lin et al. · Annals of Oncology · 2018 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17